ClinicalTrials.gov
public full text
Public Domain
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease#1072862
- Bryostatin Treatment of Moderately Severe Alzheimer's Disease#900385
- Can supermicrosurgery treat Alzheimer’s disease? - Current evidence and hope / Ashkan Rashad, Behrus Hinrichs-Puladi, Henning Wieker, Jeff Berens, Max Ulbrich, Rainer Röhrig, Frank Hölzle, Kathrin Reetz, Maurice Klein#675409
- A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment#1120231
- A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease#827596
Record · ID 866669
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive